CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives $5.77 Average Price Target from Analysts

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) have been assigned a consensus rating of “Moderate Buy” from the six ratings firms that are covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $5.77.

Separately, HC Wainwright reiterated a “neutral” rating on shares of CytomX Therapeutics in a research note on Monday, November 11th.

CytomX Therapeutics Stock Performance

CTMX opened at $1.09 on Friday. The firm has a market cap of $85.30 million, a P/E ratio of 6.41 and a beta of 1.07. The business’s fifty day moving average is $1.06 and its 200-day moving average is $1.20. CytomX Therapeutics has a 52-week low of $0.83 and a 52-week high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.23. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. The business had revenue of $33.43 million for the quarter, compared to analyst estimates of $18.92 million. During the same quarter last year, the business posted $0.04 EPS. On average, research analysts predict that CytomX Therapeutics will post -0.05 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Acadian Asset Management LLC raised its holdings in CytomX Therapeutics by 1.4% in the 2nd quarter. Acadian Asset Management LLC now owns 2,728,569 shares of the biotechnology company’s stock valued at $3,324,000 after buying an additional 37,739 shares during the last quarter. Assenagon Asset Management S.A. increased its position in CytomX Therapeutics by 32.8% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,644,168 shares of the biotechnology company’s stock valued at $1,940,000 after acquiring an additional 405,669 shares during the period. Jacobs Levy Equity Management Inc. raised its stake in shares of CytomX Therapeutics by 1.1% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,524,076 shares of the biotechnology company’s stock valued at $1,798,000 after acquiring an additional 16,359 shares during the last quarter. Congress Park Capital LLC lifted its holdings in shares of CytomX Therapeutics by 5.4% during the third quarter. Congress Park Capital LLC now owns 1,216,008 shares of the biotechnology company’s stock worth $1,435,000 after purchasing an additional 62,788 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of CytomX Therapeutics by 4.4% in the third quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company’s stock worth $948,000 after purchasing an additional 34,032 shares during the last quarter. 67.77% of the stock is currently owned by institutional investors.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.